A Phase 3 interventional study of Nivolumab and Ipilimumab in Various Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 190 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Ipilimumab
Biological: Nivolumab · Drug: Cisplatin · Drug: Fluorouracil
Drug: Cisplatin · Drug: Fluorouracil
Specified dose on specified days
Also known as: BMS-936558 (Nivolumab), Opdivo (Nivolumab)
Specified dose on specified days
Also known as: BMS-734016 (Ipilimumab), Yervoy (Ipilimumab)
Specified dose on specified days
Specified dose on specified days
Overall Survival (OS) in Participants With Tumor Cell PD-L1
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.
Time frame: From the date of randomization to up to the date of death (up to approximately 20 months)
Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1
Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.
Time frame: From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 9 months)
Overall Survival (OS) in All Randomized Participants
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.
Time frame: From the date of randomization to up to the date of death (up to approximately 88 months)
Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR
Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.
Time frame: From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 88 months)
Objective Response Rate (ORR) as Assessed by BICR
Objective response rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation as determined by BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
Time frame: From the date of randomization to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 88 months)
| Milestone | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Started | 325 | 321 | 324 |
| Completed | 322 | 310 | 304 |
| Not completed | 3 | 11 | 20 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 2 |
| Withdrew: Participant withdrew consent | 0 | 1 | 12 |
| Withdrew: Participant no longer meets study criteria | 0 | 4 | 2 |
| Withdrew: Other reasons | 1 | 2 | 1 |
| Withdrew: Disease progression | 1 | 1 | 2 |
| Withdrew: Adverse event unrelated to study drug | 1 | 3 | 1 |
| Milestone | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Started | 322 | 310 | 304 |
| Completed | 0 | 0 | 0 |
| Not completed | 322 | 310 | 304 |
| Withdrew: Disease progression | 182 | 191 | 199 |
| Withdrew: Study drug toxicity | 59 | 36 | 38 |
| Withdrew: Death | 6 | 4 | 4 |
| Withdrew: Adverse event unrelated to study drug | 19 | 26 | 11 |
| Withdrew: Participant request to discontinue study treatment | 13 | 22 | 21 |
| Withdrew: Participant withdrew consent | 3 | 4 | 12 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Maximum clinical benefit | 1 | 3 | 4 |
| Withdrew: Completed treatment as per protocol | 28 | 14 | 0 |
| Withdrew: Other reasons | 10 | 10 | 15 |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.
| Months | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Overall Survival (OS) in Participants With Tumor Cell PD-L1 | 13.70 (11.24 to 17.02) | 15.44 (11.93 to 19.52) | 9.07 (7.69 to 9.95) |
Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.
| Months | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1 | 4.04 (2.40 to 4.93) | 6.93 (5.68 to 8.34) | 4.44 (2.89 to 5.82) |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the subject was known to be alive.
| Months | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Overall Survival (OS) in All Randomized Participants | 12.747 (11.269 to 15.474) | 13.207 (11.105 to 15.671) | 10.710 (9.396 to 12.090) |
Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented progressive disease (PD) per Blinded Independent Central Review (BICR) or death due to any cause. Participants who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Participants who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on-study tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Participants who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.
| Months | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR | 2.891 (2.661 to 4.172) | 5.782 (5.520 to 6.998) | 5.618 (4.304 to 5.914) |
Objective response rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is defined as the best response designation as determined by BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.
| Percentage of participants | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Participants with baseline PD-L1 status < 1% | 20.1 (14.3 to 27.1) | 41.7 (34.1 to 49.7) | 33.7 (26.6 to 41.5) |
| Participants with baseline PD-L1 status >= 1% | 35.4 (28.0 to 43.4) | 53.2 (45.1 to 61.1) | 19.9 (13.9 to 27.0) |
| Participants with baseline PD-L1 status < 5% | 22.3 (16.7 to 28.6) | 44.8 (37.8 to 51.9) | 30.9 (24.7 to 37.7) |
| Participants with baseline PD-L1 status >= 5% | 36.7 (28.1 to 45.9) | 51.7 (42.4 to 60.9) | 20.0 (13.1 to 28.5) |
| Participants with baseline PD-L1 status < 10% | 23.3 (17.9 to 29.5) | 46.1 (39.4 to 53.0) | 29.3 (23.5 to 35.8) |
| Participants with baseline PD-L1 status >= 10% | 36.9 (27.6 to 47.0) | 50.0 (39.9 to 60.1) | 21.6 (13.9 to 31.2) |
| Participants with baseline PD-L1 status indeterminate, not evaluable, or missing | 33.3 (0.8 to 90.6) | — | 0.0 (0.0 to 84.2) |
| All randomized participants | 27.4 (22.6 to 32.6) | 47.4 (41.8 to 53.0) | 26.9 (22.1 to 32.0) |
Collected over All cause mortality was collected till 88 months and Serious and Non-Serious AEs from first dose (Day 1) to 100 days post last dose (up to 43 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivolumab + Ipilimumab | 270/325 (83.1%) | 243/322 (75.5%) | 301/322 (93.5%) |
| Arm B: Nivolumab + Chemotherapy | 273/321 (85%) | 226/310 (72.9%) | 307/310 (99%) |
| Arm C: Chemotherapy | 286/324 (88.3%) | 174/304 (57.2%) | 288/304 (94.7%) |
| Event | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 59/322 | 61/310 | 65/304 |
| PneumoniaInfections and infestations | 32/322 | 33/310 | 20/304 |
| DysphagiaGastrointestinal disorders | 12/322 | 21/310 | 16/304 |
| PyrexiaGeneral disorders and administration site conditions | 14/322 | 7/310 | 7/304 |
| Oesophageal stenosisGastrointestinal disorders | 3/322 | 9/310 | 13/304 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 13/322 | 6/310 | 1/304 |
| VomitingGastrointestinal disorders | 5/322 | 4/310 | 12/304 |
| Pneumonia aspirationInfections and infestations | 12/322 | 6/310 | 8/304 |
| Acute kidney injuryRenal and urinary disorders | 2/322 | 9/310 | 4/304 |
| Hepatic function abnormalHepatobiliary disorders | 9/322 | 0/310 | 1/304 |
| Event | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy |
|---|---|---|---|
| NauseaGastrointestinal disorders | 88/322 | 207/310 | 172/304 |
| Decreased appetiteMetabolism and nutrition disorders | 70/322 | 161/310 | 156/304 |
| AnaemiaBlood and lymphatic system disorders | 84/322 | 156/310 | 108/304 |
| ConstipationGastrointestinal disorders | 87/322 | 142/310 | 138/304 |
| StomatitisGastrointestinal disorders | 34/322 | 100/310 | 75/304 |
| DiarrhoeaGastrointestinal disorders | 84/322 | 98/310 | 63/304 |
| FatigueGeneral disorders and administration site conditions | 56/322 | 83/310 | 63/304 |
| VomitingGastrointestinal disorders | 53/322 | 77/310 | 60/304 |
| Neutrophil count decreasedInvestigations | 12/322 | 75/310 | 61/304 |
| PyrexiaGeneral disorders and administration site conditions | 76/322 | 65/310 | 48/304 |
| Age, Continuous(Years) | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 9.1 | 63.1 ± 9.2 | 63.3 ± 8.7 | 62.9 ± 9.0 |
| Sex: Female, Male(Participants) | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy | Total |
|---|---|---|---|---|
| Female | 56 | 68 | 49 | 173 |
| Male | 269 | 253 | 275 | 797 |
| Race/Ethnicity, Customized(Participants) | Arm A: Nivolumab + Ipilimumab | Arm B: Nivolumab + Chemotherapy | Arm C: Chemotherapy | Total |
|---|---|---|---|---|
| White | 79 | 85 | 84 | 248 |
| Black or African American | 4 | 1 | 6 | 11 |
| American Indian or Alaska Native | 1 | 2 | 1 | 4 |
| Asian Indian | 1 | 4 | 3 | 8 |
| Chinese | 71 | 74 | 70 | 215 |
| Japanese | 131 | 126 | 137 | 394 |
| Asian Other | 28 | 23 | 17 | 68 |
| Other | 10 | 6 | 6 | 22 |
Showing the first 100 of 190 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Jan 2021, 42 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab · Cisplatin · Fluorouracil